JP7640454B2 - Ｌｒｒｋ２の野生型および変異型の分解誘導剤 - Google Patents

Ｌｒｒｋ２の野生型および変異型の分解誘導剤 Download PDF

Info

Publication number
JP7640454B2
JP7640454B2 JP2021520116A JP2021520116A JP7640454B2 JP 7640454 B2 JP7640454 B2 JP 7640454B2 JP 2021520116 A JP2021520116 A JP 2021520116A JP 2021520116 A JP2021520116 A JP 2021520116A JP 7640454 B2 JP7640454 B2 JP 7640454B2
Authority
JP
Japan
Prior art keywords
compound
lrrk2
formula
degradation
term
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021520116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504762A (ja
JP2022504762A5 (https=
Inventor
ナサナエル エス． グレイ，
ジョン ハッチャー，
Original Assignee
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Publication of JP2022504762A publication Critical patent/JP2022504762A/ja
Publication of JP2022504762A5 publication Critical patent/JP2022504762A5/ja
Priority to JP2024127950A priority Critical patent/JP2024156881A/ja
Application granted granted Critical
Publication of JP7640454B2 publication Critical patent/JP7640454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2021520116A 2018-10-16 2019-10-16 Ｌｒｒｋ２の野生型および変異型の分解誘導剤 Active JP7640454B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024127950A JP2024156881A (ja) 2018-10-16 2024-08-02 Ｌｒｒｋ２の野生型および変異型の分解誘導剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862746283P 2018-10-16 2018-10-16
US62/746,283 2018-10-16
US201962884410P 2019-08-08 2019-08-08
US62/884,410 2019-08-08
PCT/US2019/056537 WO2020081682A1 (en) 2018-10-16 2019-10-16 Degraders of wild-type and mutant forms of lrrk2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024127950A Division JP2024156881A (ja) 2018-10-16 2024-08-02 Ｌｒｒｋ２の野生型および変異型の分解誘導剤

Publications (3)

Publication Number Publication Date
JP2022504762A JP2022504762A (ja) 2022-01-13
JP2022504762A5 JP2022504762A5 (https=) 2022-10-24
JP7640454B2 true JP7640454B2 (ja) 2025-03-05

Family

ID=70284195

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021520116A Active JP7640454B2 (ja) 2018-10-16 2019-10-16 Ｌｒｒｋ２の野生型および変異型の分解誘導剤
JP2024127950A Withdrawn JP2024156881A (ja) 2018-10-16 2024-08-02 Ｌｒｒｋ２の野生型および変異型の分解誘導剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024127950A Withdrawn JP2024156881A (ja) 2018-10-16 2024-08-02 Ｌｒｒｋ２の野生型および変異型の分解誘導剤

Country Status (7)

Country Link
US (1) US20210361774A1 (https=)
EP (1) EP3866801A4 (https=)
JP (2) JP7640454B2 (https=)
CN (1) CN112888460A (https=)
AU (1) AU2019361964C1 (https=)
CA (1) CA3115818A1 (https=)
WO (1) WO2020081682A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021194878A1 (en) * 2020-03-21 2021-09-30 Arvinas Operations, Inc. Selective modulators of mutant lrrk2 proteolysis and associated methods of use
JP7644139B2 (ja) * 2020-03-21 2025-03-11 アルヴィナス・オペレーションズ・インコーポレイテッド インダゾール系化合物及び関連使用方法
JP2024512501A (ja) * 2021-03-19 2024-03-19 アルヴィナス・オペレーションズ・インコーポレイテッド インダゾール系化合物及び関連使用方法
CN117321046A (zh) * 2021-03-19 2023-12-29 阿维纳斯企业公司 基于吲唑的化合物和相关使用方法
US20240308982A1 (en) * 2021-07-08 2024-09-19 Dana-Farber Cancer Institute, Inc. Degraders of wild-type and mutant forms of lrrk2 and uses thereof
KR20240171138A (ko) * 2022-04-04 2024-12-06 브레닉 테라퓨틱스 인코포레이티드 Lrrk2 저해제
EP4276097A1 (en) 2022-05-10 2023-11-15 University Of Dundee Aminopyrimidinyl derivatives for the treament of parkinson's disease
TW202515874A (zh) 2023-09-28 2025-04-16 美商亞文納營運公司 用於靶向降解富含白胺酸之重複激酶２（ｌｒｒｋ２）的基於苯并咪唑及苯并咪唑酮之ｐｒｏｔａｃ化合物
KR20250054737A (ko) * 2023-10-16 2025-04-23 주식회사 아스트로젠 신규한 분자 접착제의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151360A1 (en) 2010-06-04 2011-12-08 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as lrrk2 modulators
WO2013079497A1 (fr) 2011-12-02 2013-06-06 Morpho Procede et dispositif de suivi d'un objet dans une sequence d'au moins deux images
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
JP2018502097A (ja) 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
US8461147B2 (en) * 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
KR101366613B1 (ko) * 2012-07-11 2014-02-26 사회복지법인 삼성생명공익재단 아자티오프린을 유효성분으로 함유하는 뇌종양 또는 테모달 내성 교모세포종 예방 또는 치료용 약학적 조성물
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3270917A4 (en) * 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109790143A (zh) * 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
GB201610147D0 (en) * 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
AU2018219292B2 (en) * 2017-02-08 2024-09-26 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
JP7227912B2 (ja) * 2017-02-08 2023-02-24 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド キメラ抗原受容体の調節
KR101923852B1 (ko) * 2017-02-24 2018-11-29 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151360A1 (en) 2010-06-04 2011-12-08 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as lrrk2 modulators
WO2013079497A1 (fr) 2011-12-02 2013-06-06 Morpho Procede et dispositif de suivi d'un objet dans une sequence d'au moins deux images
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP2018502097A (ja) 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation

Also Published As

Publication number Publication date
JP2024156881A (ja) 2024-11-06
US20210361774A1 (en) 2021-11-25
WO2020081682A1 (en) 2020-04-23
JP2022504762A (ja) 2022-01-13
AU2019361964B2 (en) 2025-01-23
EP3866801A1 (en) 2021-08-25
CN112888460A (zh) 2021-06-01
AU2019361964A1 (en) 2021-03-18
AU2019361964C1 (en) 2025-06-26
CA3115818A1 (en) 2020-04-23
EP3866801A4 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
JP7640454B2 (ja) Ｌｒｒｋ２の野生型および変異型の分解誘導剤
US12110292B2 (en) Ligands to cereblon (CRBN)
US12466809B2 (en) CDK2/5 degraders and uses thereof
US11542251B2 (en) IRAK degraders and uses thereof
US12551563B2 (en) ERK5 degraders as therapeutics in cancer and inflammatory diseases
US20210038599A1 (en) Small molecule degraders of polybromo-1 (pbrm1)
US20220040317A1 (en) Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
US20260027217A1 (en) Degraders that target alk and therapeutic uses thereof
US20220177466A1 (en) Degraders of kelch-like ech-associated protein 1 (keap1)
US20250066326A1 (en) Bcl6 degraders and uses thereof
JP7626721B2 (ja) 小分子標的ブロモ／アセチルタンパク質およびその使用
US20240277852A1 (en) Inhibitors and degraders of pip4k protein
US20230192644A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
US20240308982A1 (en) Degraders of wild-type and mutant forms of lrrk2 and uses thereof
US20250163024A1 (en) Chemical targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4) and use in diffuse intrinsic pontine glioma (dipg)
US20230226195A1 (en) Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system
US20240245786A1 (en) Small molecule degraders of phosphatidylinositol-5-phosphate 4-kinase type 2 and uses thereof
US20240374737A1 (en) Erk5 degraders and uses thereof
US20230133538A1 (en) Targeted degraders of aberrant tau based on the pet tracer pbb3
US20240409574A1 (en) Small molecules for dot1l degradation and uses thereof
US20230226196A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
US20260001862A1 (en) Quinoxalinedione and pyrido[2,3-b]pyrazine-2,3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250220

R150 Certificate of patent or registration of utility model

Ref document number: 7640454

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150